Robotic prostatectomy, FoundationOne Liquid CDx test

November 19, 2020

1 min read

We were unable to process your request. Please try again later. If you continue to have this issue please contact

A novel technique for robotic prostatectomy allowed men to regain continence early after prostate cancer surgery, according to a recent study. It was the top story in hematology/oncology last week.

Another top story was about the FDA approval of FoundationOne Liquid CDx test (Foundation Medicine) as a companion diagnostic test for several cancer therapies.

genetic testing

Source: Adobe Stock

Read these and more top stories in hematology/oncology below:

Novel technique enables men to regain continence early after prostate cancer surgery

A novel “hood technique” for robotic prostatectomy allowed men with prostate cancer to achieve early return of urinary continence without compromising positive surgical margins, according to study results published in European Urology. Read more.

FDA approves FoundationOne Liquid CDx as companion diagnostic for several cancer therapies

The FDA approved the FoundationOne Liquid CDx test as a companion diagnostic device to help identify multiple additional biomarkers in cell-free DNA isolated from plasma, according to a press release from the agency. Read more.

NIH grant to fund study of ‘chemo brain’ among children

So-called “chemo brain” is a functionally limiting and frustrating consequence of curative treatment for cancer. For some children, chemotherapy may disrupt essential cognitive functions such as sensory processing, memory and attention. Read more.

APPs have a growing role in the oncology workforce

It is well-documented that cancer care in the U.S. is facing an impending workforce crisis. Among the potential solutions to this workforce problem, one of the most frequently cited is the enhanced use of advanced practice providers. Read more.

Radiation therapy safe before CAR T-cell infusion for advanced multiple myeloma

Localized radiation therapy appeared to be safe before treatment with chimeric antigen receptor T cells for relapsed or refractory multiple myeloma, according to study results presented at the virtual ASTRO Annual Meeting. Read more.

Source link